ROCKVILLE, Md. -- Sequella, a clinical-stage pharmaceutical company commercializing novel antibiotics to treat life-threatening infectious diseases, today announced that it has licensed Pfizer Inc’s exclusive worldwide rights to develop and commercialize sutezolid, a Phase 2 oxazolidinone antibiotic currently in development for the treatment of tuberculosis (TB).

16 July 2013 - Abuja, Nigeria - African leaders meeting here Monday and Tuesday renewed commitments to fight AIDS, tuberculosis (TB) and malaria and undertook to scale up actions aimed at eliminating the three epidemics as part of an overall goal to eliminate extreme poverty by 2030.

ABUJA, Nigeria, 15 July 2013—A report launched today at the Special Summit of the African Union on HIV/AIDS, Tuberculosis and Malaria highlights increased, targeted health spending as an essential foundation to greater economic growth and development in Africa. The report, Abuja +12: Shaping the future of health in Africa, published by the African Union (AU) and the Joint United Nations Programme on HIV/AIDS (UNAIDS), reviews progress made since the AU’s 2001 Abuja Declaration—in which leaders pledged to mobilize domestic and international resources for health and remove barriers to the AIDS response—highlights remaining gaps, and prioritizes next steps.

Civil society reaction to the TB drug stockouts in India and full media coverage of the public health crisis.

June 17, 2013, Médecins Sans Frontières
India must address worrying stock out of tuberculosis drugs

June 21, 2013, TB Online
Open letter to Indian Prime Minister: Stop the TB drug stockouts

June 26, 2013, TB Online
India first ever TB demonstration

Full media coverage (download pdf)

Some photos from the civil society demonstration outside the federal health ministry in New Delhi, India, June 26, 2013:

OVERCROWDED classrooms and poor ventilation increase the risk of pupils contracting tuberculosis at schools, say doctors from the Desmond Tutu HIV Centre – prompting education rights group Equal Education to call the matter a “public health emergency”.

You can download from here information about the Sentinel Project's upcoming workshop on inclusion of children in TB surveys, to be held at the Union Conference on October 31, 2013.

Tens of thousands of children are sick with multidrug-resistant forms of tuberculosis (MDR-TB), but there are limited child-friendly delivery systems for second-line medications. This case study presents the development of a granular dosing spoon pediatric delivery system for para-aminosalicylic acid. This product is the first of its kind for MDR-TB and could serve as a model for the development of other urgently needed pediatric delivery systems for second-line anti-tuberculosis drugs.